20. Adrenoleukodystrophy Clinical trials / Disease details
Clinical trials : 61 / Drugs : 90 - (DrugBank : 31) / Drug target genes : 23 - Drug target pathways : 126
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04303416 (ClinicalTrials.gov) | March 9, 2020 | 6/3/2020 | Plasma Exchange With Albumin in AMN Patients | Effect of Plasma Exchange With Albumin in Patients With Adrenomyeloneuropathy: Unicentric, Single Arm, Proof of Concept Study. | Adrenomyeloneuropathy;Adrenoleukodystrophy | Drug: Albumin solution | Onofre, Aurora Pujol, M.D. | NULL | Completed | 18 Years | 65 Years | Male | 5 | Phase 2/Phase 3 | Spain |
| 2 | EUCTR2019-004733-17-ES (EUCTR) | 25/02/2020 | 20/12/2019 | Plasma exchange by albumin replacement in Adrenomyeloneuropathy | Effect of plasma exchange by albumin replacement in Adrenomyeloneuropathy: unicentric, single arm, proof of concept trial | Adrenomyeloneuropathy MedDRA version: 20.0;Level: LLT;Classification code 10069075;Term: Adrenomyeloneuropathy without cerebral involvement;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: Albunorm® 5%, Product Name: Albumin INN or Proposed INN: ALBUMIN Other descriptive name: ALBUMIN | Aurora Pujol Onofre | NULL | Authorised-recruitment may be ongoing or finished | Female: no Male: yes | 5 | Phase 2 | Spain |